Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
AssigneesUniversite De Lille, Centre National De La Recherche Scientifique, Institut Gustave Roussy, Cellvax, University Paris-Saclay
InventorsNadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
Life of this patent
Estimating the term…
Abstract
The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
Claims6
A neutralizing antibody directed against Galectin-9 and inhibiting the suppressor activity of regulatory T lymphocytes, wherein the antibody is a humanized antibody, having as CDRs the six CDRs defined by:
- the amino acid sequence SEQ ID NO:
- 2 in the region H-CDR1;
- the amino acid sequence SEQ ID NO:
- 3 in the region H-CDR2;
- the amino acid sequence SEQ ID NO:
- 4 in the region H-CDR3;
- the amino acid sequence SEQ ID NO:
- 6 in the region L-CDR1;
- the amino acid sequence SEQ ID NO:
- 7 in the region L-CDR2;
- and
- the amino acid sequence SEQ ID NO:
- 8 in the region L-CDR3.
A neutralizing antibody directed against Galectin-9 and inhibiting the suppressor activity of regulatory T lymphocytes, wherein the antibody is a humanized antibody, having as CDRs the six CDRs defined by:
- the amino acid sequence SEQ ID NO:
- 11 in the region H-CDR1;
- the amino acid sequence SEQ ID NO:
- 12 in the region H-CDR2;
- the amino acid sequence SEQ ID NO:
- 13 in the region H-CDR3;
- the amino acid sequence SEQ ID NO:
- 15 in the region L-CDR1;
- the amino acid sequence SEQ ID NO:
- 16 in the region L-CDR2;
- and
- the amino acid sequence SEQ ID NO:
- 17 in the region L-CDR3.
Dependencies are inferred from the claim text.